dMed is Now Caidya! Caidya is a global, multi-therapeutic clinical research organization (CRO) dedicated to advancing healthcare innovation and accelerating the development of new therapies. With full-service capabilities and a strategic footprint in 23 countries and regions, our global network provides broad access to diverse patient populations across the Americas, Europe, and APAC. Caidya’s in-depth therapeutic and operational expertise helps partners conduct studies with greater efficiency and confidence. Our commitment to excellence and data-driven decision-making ensures the highest quality standards across all phases of the drug development process. Caidya provides comprehensive clinical trial services from regulatory strategy and submissions, clinical operations, biometrics, and quality management, through post-approval surveillance. Following the merger of dMed and Clinipace, Caidya launched with a clear purpose to liberate clinical research and bring life-changing therapies to our global community.
$50M sweet spot round size
2016
$50M
from 2 investors over 1 rounds
dMed Biopharmaceutical Co., Ltd. dba Caidya raised $50M on August 10, 2021
Investors: SpringHill Management and + 3 Other investors